In this issue:
- Opportunistic HPV self-testing
- Experiences and knowledge of cervical screening in young NZ women
- GLP-1 receptor agonists + progestins and endometrial cancer risk
- Molecular profile-based adjuvant treatment of high-intermediate-risk endometrial cancer
- Lenvatinib + pembrolizumab in previously treated advanced endometrial cancer
- Adjuvant chemotherapy in stage I ovarian CCC
- Palbociclib in patients with recurrent ovarian cancer
- Ipilimumab + nivolumab for CCC of the gynaecological tract
- Rezatapopt in TP53 Y220C-mutated tumours
- HPV-associated vs HPV independent vulvar SCC
Please login below to download this issue (PDF)